In an interview with Targeted OncologyTM, Ranjit Goudar, MD, of Virginia Oncology Associates, discusses the ongoing barriers ...

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side effects, next trials.

Dr Joyce Ohm discusses the ethical questions raised by genome sequencing, from data ownership to reporting mutations of unknown significance. This is part 3 of an interview. Watch part 1 and part 2.

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

A Big Ten Cancer Research Consortium project is testing counter-marketing, plain-language messages tailored for social media ...

Community oncology expands hereditary cancer genetic testing with team-based counseling, trained clinicians, and structured ...

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...

Early termination after 68 randomizations reflected a 61% serious AE rate and 19% treatment-related deaths with radiotherapy, ...

Dr Joyce Ohm explains how sequencing tumor genomes reveals the mutations needed to design targeted cell and gene therapies for cancer patients. In part 2 of this interview, Joyce Ohm, PhD, explains ...